Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2007-10-23
2007-10-23
Anderson, Rebecca (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
C544S365000
Reexamination Certificate
active
11108587
ABSTRACT:
Provided herein is a compound having the formula (I):Wherein said compounds are useful for the treatment of psychiatric disorders including but not limited to depression, generalized anxiety, eating disorders, dementia, panic disorder, and sleep disorders. The compounds may also be useful in the treatment of gastrointestinal disorders, cardiovascular regulation, motor disorders, endocrine disorders, vasospasm and sexual dysfunction. The compounds are 5HT1Band 5HT1Dantagonists.
REFERENCES:
patent: 3862143 (1975-01-01), Klutchko et al.
patent: 3937837 (1976-02-01), Klutchko et al.
patent: 4189498 (1980-02-01), Kabbe et al.
patent: 4307020 (1981-12-01), Kabbe et al.
patent: 4631282 (1986-12-01), Cassidy et al.
patent: 5112856 (1992-05-01), Gaginella et al.
patent: 5171865 (1992-12-01), Kurono et al.
patent: 5403842 (1995-04-01), Leonardi et al.
patent: 5420151 (1995-05-01), Hammarberg et al.
patent: 5605896 (1997-02-01), Leonardi et al.
patent: 5914401 (1999-06-01), Egle et al.
patent: 5965575 (1999-10-01), Peglion et al.
patent: 5968954 (1999-10-01), Peglion et al.
patent: 6034256 (2000-03-01), Carter et al.
patent: 6040308 (2000-03-01), Hausler et al.
patent: 6153625 (2000-11-01), Peglion et al.
patent: 6384225 (2002-05-01), Berg et al.
patent: 6387899 (2002-05-01), Berg et al.
patent: 6479497 (2002-11-01), Berg et al.
patent: 6552054 (2003-04-01), Yasuma et al.
patent: 6812225 (2004-11-01), Pierson et al.
patent: 7026314 (2006-04-01), Chapdelaine et al.
patent: 7045514 (2006-05-01), Pierson et al.
patent: 2005/0096312 (2005-05-01), Haeberlein et al.
patent: 2006/0178372 (2006-08-01), Haeberlein et al.
patent: 2331138 (1974-01-01), None
patent: 0000377 (1979-01-01), None
patent: 0017578 (1980-10-01), None
patent: 0104018 (1984-03-01), None
patent: 0223744 (1987-05-01), None
patent: 0546389 (1993-06-01), None
patent: 2177084 (1987-01-01), None
patent: 2001-261657 (2001-09-01), None
patent: 90/12795 (1990-11-01), None
patent: 91/09853 (1991-07-01), None
patent: WO9109853 (1991-07-01), None
patent: WO9429293 (1994-06-01), None
patent: 97/07120 (1997-02-01), None
patent: WO9734883 (1997-09-01), None
patent: WO9827058 (1998-06-01), None
patent: WO9827080 (1998-06-01), None
patent: 99/05140 (1999-02-01), None
patent: WO9914207 (1999-03-01), None
patent: WO9914212 (1999-03-01), None
patent: WO9914213 (1999-03-01), None
patent: WO 0012623 (2000-03-01), None
patent: 00/40554 (2000-07-01), None
patent: 01/16127 (2001-03-01), None
patent: WO 0116127 (2001-03-01), None
PCT Written Opinion PCT/SE02/00070.
PCT Written Opinion PCT/SE02/00069.
PCT Written Opinion PCT/SE02/00068.
International Search Report for International Application No. PCT/SE02/00070.
International Search Report for International Application No. PCT/SE02/00069.
International Search Report for International Application No. PCT/SE02/00068.
Barnes, et al., “A review of central 5-HT receptors and their funciton”, Neuropharmacology 38, 1083-1152, (1999).
Berg, et al., “(R)-(+)-2-[[[3-( Morpholinomethyl)-2H-chromen-8-yl]oxy]methyl]morpholine Methanesulfonate: A new selective rat 5-Hydroxytryptamine1B receptor antagonist”, J. Med. Chem. vol. 41, 1934-1942 (1998).
Cryan, et al., “5-HT1A and Beyond: The Role of Serotonin and its Receptors in Depresion and the Antidepressant Response”, Hum. Psychopharmacol. Clin. Exp., 15, 113-115 (2000).
Gaster, et al., “The Selective 5-HT1b Receptor Inverse Agonist . . . (SB-224289) Potently Blocks Terminal 5-HT Autoreceptor Function Both in Vitro and in Vivo” J. Med. Chem., 41, 1218-1235 (1998).
Halazy, et al., “5-HT1B/1D antagonists and depression”, Exp. Opin. Ther. Patents, 7(4) 339352 (1997).
Raposo, et al., “The effect of chromenone receptors on the selectivity of the reaction between pyrrolidine and 5-Hydroxymethyl-2-(5H)-furanone”, Chemistry Letters, 173-174 (1997).
Russel, et al., “3-[3-(piperidin-1-yl)propyl]indoles as Highly Selective h5-HT1D Receptor Agonist”, J. Med. Chem., 42, 4981-5001, (1999).
Office Action for U.S. Appl. No. 10/466,565, Dated Aug. 21, 2006.
Communication pursuant to Article 96(2) EPO for Corresponding EP Application No. 02729622.7 dated Oct. 5, 2006.
Svenningsson, et al., “Alterations in 5-HT1B Receptor Function by p11 in Depression-Like States”, Science, vol. 311, Jan. 6, 2006, pp. 77 to 80.
Trevor Sharp, “A New Molecule to Brighten the Mood”, Science, vol. 311, Jan. 6, 2006, pp. 45 to 46.
Chapdelaine Marc
Davenport Timothy
Haeberlein Markus
Horchler Carey
McCauley John P.
Anderson Rebecca
AstraZeneca AB
Kondrad Karen H.
LandOfFree
Therapeutic heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3864245